Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$94.35 USD

94.35
239,975

+0.59 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hill-Rom (HRC) Q4 Earnings Top Estimates on All-Line Growth

by Zacks Equity Research

Hill-Rom (HRC) benefits from a robust year-over-year revenue increase on solid domestic growth in Q4, driven by a strong segmental performance at both Patient Support Systems and Front Line Care.

Integer Holdings (ITGR) Beats on Q3 Earnings and Revenues

by Zacks Equity Research

Integer Holdings (ITGR) gains from solid Medical sales contribution in Q3; 2018 guidance solid.

Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Significant margin contraction hurts Allscripts' (MDRX) results in Q3; decline in bookings discourages.

Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat

by Zacks Equity Research

Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.

Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive

by Zacks Equity Research

Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.

Abiomed (ABMD) Q2 Earnings Beat, Impella Maintains Momentum

by Zacks Equity Research

Abiomed's (ABMD) flagship Impella sees a solid Q2; fiscal 2019 outlook raised.

Bruker (BRKR) Q3 Earnings Surpass Estimates, Guidance Up

by Zacks Equity Research

We are upbeat about Bruker's (BRKR) current focus on product development through higher R&D.

Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.

Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat

by Zacks Equity Research

Bio-Rad's (BIO) solid revenue growth in geographies like North America, China and Asia Pacific in Q3 buoys optimism.

IDEXX Laboratories (IDXX) Beats on Q3 Earnings, EPS View Up

by Zacks Equity Research

IDEXX Laboratories' (IDXX) stellar performance in Q3 reflects strong sales at the CAG business.

PerkinElmer (PKI) Misses on Q3 Earnings, Slashes EPS View

by Zacks Equity Research

Perkinelmer (PKI) gains from segmental performances in Q3; lowers 2018 EPS view.

Accuray (ARAY) Q1 Loss Wider Than Expected, Gross Orders Rise

by Zacks Equity Research

Accuray's (ARAY) flagship Radixact System drives Q1 results; strong EBITDA guidance instils hope.

Express Scripts (ESRX) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.

Baxter (BAX) Earnings Beat, Revenues Lag Estimates in Q3

by Zacks Equity Research

Baxter (BAX) gains from Renal Care and Advanced Surgery units in Q3; APAC sales soft.

Cardiovascular Systems' (CSII) Q1 Loss Wider Than Expected

by Zacks Equity Research

Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q1.

NextGen Healthcare (NXGN) Beats on Q2 Earnings, Lags Revenues

by Zacks Equity Research

NextGen Healthcare (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q2; lowers fiscal 2019 view.

Fresenius Medical (FMS) Beats on Q3 Earnings, Lags Revenues

by Zacks Equity Research

Lower North America sales hurt Fresenius Medical's (FMS) Q3 results. Care Coordination margin improves significantly.

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q3

by Zacks Equity Research

At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues in Q3.

Ecolab (ECL) Misses on Q3 Earnings & Revenues, Lowers View

by Zacks Equity Research

Ecolab (ECL) misses estimates despite strong growth in Global Industrial and Global Institutional; 2018 guidance dull.

QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Merit Medical (MMSI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 11.90% and 1.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q3 Earnings Preview: Here's What to Look Out For

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.